Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Burgoyne, Adam M
ROWAN, NCT05063565 / 2021-001907-33: TheraSphere With Durvalumab and Tremelimumab for HCC	Recruiting	2	100	Europe, US	TheraSphere Y-90 glass microsphere therapy, Durvalumab (Imfinzi) immunotherapy, Tremelimumab immunotherapy	Boston Scientific Corporation, Biocompatibles UK Ltd	Hepatocellular Carcinoma	06/27	06/27
NCT05733598: Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Recruiting	2	30	US	RP2, Bevacizumab, Avastin, Atezolizumab, Tecentriq	Replimune Inc., Roche Pharma AG	Hepatocellular Carcinoma	12/27	07/28
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas	Recruiting	1	321	Europe, US	INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide	Inhibrx Biosciences, Inc	Colorectal Adenocarcinoma, Ewing Sarcoma	06/26	12/26